Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632
This examiner grants 43% of resolved cases
Khoa Nhat Tran is an examiner in Tech Center 1600, Art Unit 1632. The examiner has 88 resolved cases. The data shows an allowance rate of 43.2 percent and an interview lift of 53.3 percent. The median days to allowance for these cases is 1535.
The 53.3 percent interview lift is a significant figure when compared to the 43.2 percent base allowance rate. This indicates that conducting an interview is a method for increasing the likelihood of an allowance. The 1535 day median pendency is the timeframe applicants can expect when navigating the resolved cases handled by this examiner in Art Unit 1632. Practitioners can consider how these metrics influence the overall prosecution timeline.
With 88 resolved cases, the examiner's statistics provide a view of the prosecution landscape. Practitioners can use the 43.2 percent allowance rate to assess the probability of a grant. The 53.3 percent lift and the Tech Center 1600 environment are factors for prosecution strategy. These data points help in setting expectations for clients.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17616283 | APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF | Final Rejection | Novo Nordisk A/S |
| 17842715 | CULTURE SYSTEM AND METHODS FOR IMPROVED MODELING OF NEUROLOGICAL CONDITIONS | Final Rejection | Genentech, Inc. |
| 18684155 | ANTIGEN PRESENTING CELL/TARGET CELL HYBRIDOMA-DERIVED VACCINES | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17921739 | Methods for Generating Thymic Cells in Vitro | Non-Final OA | The Regents of the University of California |
| 17262460 | Treatment of Vascular Occlusion by Activation of Notch Signaling | Non-Final OA | The Regents of the University of California |
| 17250791 | METHODS OF CULTURING PODOCYTES AND COMPOSITIONS THEREOF | Final Rejection | Beth Israel Deaconess Medical Center, Inc. |
| 18633827 | METHODS AND COMPOSITIONS FOR DELIVERY OF IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-BRAIN BARRIER TO TREAT BRAIN CANCER | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 17681113 | METHODS OF GENERATING AND ISOLATING MIDBRAIN DOPAMINE NEURONS | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17319495 | STEM CELL-BASED MULTIPLEX METHODS AND COMPOSITIONS | Final Rejection | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17921606 | METHODS FOR ISOLATING AND CULTURING TUMOR CELLS | Final Rejection | Georgetown University |
| 18195223 | COLD PLASMA TREATMENT MEDIATED TUMOR SPECIFIC T CELL THERAPY | Non-Final OA | Jerome Canady Research Institute for Advanced Biological and Technological Sciences |
| 17310007 | FIBROBLAST REGENERATIVE CELLS | Non-Final OA | Figene, LLC |
| 17443623 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Final Rejection | Amphera B.V. |
| 17443656 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Non-Final OA | Amphera B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy